Sisram Medical 1H FY26 swings to IFRS net loss of US$1.16 million; revenue rises 3.6% to US$171.4 million

• Sisram Medical Ltd. posted revenue of US$171.4 million, up 3.6% year on year.
• Profit attributable to owners turned to a loss of US$1.16 million; profit before tax fell 80.8% to US$2.26 million.
• Gross margin narrowed 3.3 percentage points to 56.7%, while gross profit slipped 2.1% to US$97.2 million.
• Adjusted net profit fell 57.9% to US$5 million, on higher operating expenses tied to injectables investment in China.
• International revenue excluding North America rose 16.7% to US$127 million; injectables revenue climbed 54.2% to US$22.2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290718), on August 19, 2026, and is solely responsible for the information contained therein.